Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guérin immunotherapy

International Journal of Urology

Volumn 14, Issue 2, 2007, Pages 140-146

  Shintani, Yasuyo ^a   Sawada, Yoshihisa ^a   Inagaki, Takeshi ^a   Kohjimoto, Yasuo ^a   Uekado, Yasunari ^a   Shinka, Toshiaki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bladder neoplasm; Immunotherapy; Intravesical instillation; Mycobacterium bovis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INSTILLATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; KAPLAN MEIER METHOD; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SUPERFICIAL CANCER; SURVIVAL RATE; SURVIVAL TIME; URINALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 33846324801     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01696.x     Document Type: Article

References (14)

1. Malkowicz SB. Management of superficial bladder cancer. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds). Campbell's Urology, 8th edn. WB Saunders, Philadelphia, 2002; 2785-802.
2. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol. 1976; 116: 180-3.
3. Lamm D. Bacillus Calmette-Guérin immunotherapy for bladder cancer. J. Urol. 1985; 134: 40-7.
4. Shinka T, Hirano A, Uekado Y, Kyoku I, Aoshi H, Ohkawa T. Intravesical bacillus Calmette-Guérin treatment for superficial bladder tumours. Br. J. Urol. 1989; 63: 610-15.
5. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353: 1689-94.
6. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. J. Urol. 2003; 170: 964-9.
7. Sawada Y, Shinka T, Hagino K, Ohkawa T. [Studies on mechanisms of action of intravesical bacillus Calmette-Guérin immunotherapy in patients with superficial bladder cancers: detection of granulocyte-macrophage colony stimulating factor in urine.] Ann. Soc. BCG BRM Immunother. 1991; 15: 63-8 (in Japanese).
8. Sobin LH, Wittekind C. International Union Against Cancer (UICC). Urinary bladder. In: Sobin LH, Wittekind C (eds). TNM: Classification of Malignant Tumors. Wiley-Liss, New York, 1997; 187-90.
9. Ratliff TL, Palmer JO, McGarr JA, Brown EJ. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res. 1987; 47: 1762-6.
10. Ohishi K, Katayama N, Mitani H et al. Efficient ex vivo generation of human dendritic cells mobilized CD34+ peripheral blood progenitors. Int. J. Hematol. 2001; 74: 287-96.
11. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. J. Immunol. 1999; 163: 4246-52.
12. Maki Y, Nasu Y, Tsusima T, Kumon H, Ohmori H. Intravesical bacillus Calmette-Guérin therapy for carcinoma in situ of the bladder and urinary cytokines. Nishinihon J. Urol. 1998; 60: 698-702.
13. Thalmann GN, Dewald B, Baggiolini M, Studer UE. Interleukin-8 expression in the urine after bacillus Calmette-Guérin therapy: a potential prognostic factor of tumor recurrence and progression. J. Urol. 1997; 158: 1340-4.
14. de Boer EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH, Schamhart DH. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol. Res. 1997; 25: 31-4.